Litigation

Coalition for Affordable Drugs VI LLC v. Celgene Corp.

institution denied

IPR2015-01169

Auto-generating section 1 of 5: Case overview & background…

Each section takes ~30-60s with web-search grounding. Keep this tab open — sections will fill in below as they complete.

Court: Patent Trial and Appeal Board (PTAB)
Filed: 2015-05-07
Terminated: 2015-11-16

Patents at issue (1)

Plaintiffs (1)

π Coalition for Affordable Drugs VI LLC

Defendants (1)

Δ Celgene Corp.

Summary

PTAB inter partes review petition challenging U.S. 5,635,517, filed by Coalition for Affordable Drugs VI LLC against Celgene. The Board denied institution on Nov. 16, 2015, and a motion for sanctions was also denied.

Case overview & background

Plain-language overview of the case: parties, accused product, patents at issue, and why the suit matters.

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Key legal developments & outcome

Major rulings, motions, claim construction, settlements, and the present posture or final disposition.

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

In the news

What the press has reported about this case, summarized with links to the source articles.

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Plaintiff representatives

Counsel of record for the plaintiff(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Defendant representatives

Counsel of record for the defendant(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Record id: 5635517-ipr2015-01169 · edit in Admin

Further reading

What is a patent?
A patent is a deal between an inventor and the government — a 20-year monopoly in exchange for public disclosure. Most patents that get litigated would not survive serious scrutiny.
Patent term and expiration
Patents don't last forever. They don't even reliably last 20 years. The expiration date that actually matters depends on the earliest filing date, the maintenance schedule, and any USPTO or FDA delays the patent owner can claim back.
KSR International v. Teleflex (2007)
Pre-KSR, an obviousness rejection required explicit teaching, suggestion, or motivation in the prior art. Post-KSR, common sense, design needs, and predictable variations all do the work — and most patents don't survive.
Patent trolls in 2025: the year in numbers
2025 was a banner year for patent trolls — and not by accident. Filings surged while the defendant's cheapest weapon, the PTAB, was quietly taken off the table. Here's what the reporting shows, and why the two are connected.
How to read a patent claim chart
The claim chart is where the plaintiff's case actually lives. The complaint is a pitch deck; the chart is the homework — and most patent troll homework doesn't survive a careful read.

All resources →